AC
TRIB

Aristides Capital’s Trinity Biotech TRIB Stock Holding History

Aristides Capital’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,611
Closed -$12K – 359
2023
Q4 		$12K Sell
5,611
-26,852
-83% -$64.1K ﹤0.01% 264
2023
Q3 		$119K Hold
32,463
– – 0.05% 150
2023
Q2 		$154K Hold
32,463
– – 0.06% 150
2023
Q1 		$153K Sell
32,463
-11,443
-26% -$59K 0.08% 128
2022
Q4 		$217K Sell
43,906
-2,396
-5% -$14.5K 0.11% 164
2022
Q3 		$248K Sell
46,302
-1,834
-4% -$11.8K 0.19% 110
2022
Q2 		$295K Buy
+48,136
New +$294K 0.2% 103

Other funds holding TRIB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Aristides Capital's TRIB Position: Q1 2024 in Review

Aristides Capital sold out of Trinity Biotech (TRIB) in Q1 2024, closing a stake of 5,611 shares — an estimated $12K sold.

Aristides Capital first reported a position in TRIB in Q2 2022 and held it in 7 quarters. The position peaked at $295K in Q2 2022. 19 funds tracked by Wall St. Rank hold TRIB as of Q1 2024.

  • Aristides Capital reported no remaining Trinity Biotech position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 5,611 Trinity Biotech shares in Q1 2024, an estimated $12K.
  • Aristides Capital first reported a position in Trinity Biotech in Q2 2022 and held it in 7 quarters.
  • Aristides Capital's Trinity Biotech position peaked at $295K in Q2 2022.
  • 19 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.